Disc Medicine IRON Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -35.8%0.0pp | -35.9%-1.1pp | -34.8%-8.4pp | -26.4%-3.0pp | -23.3%+4.4pp | |
| Return on assets | -33.1%-0.6pp | -32.6%-0.4pp | -32.2%-7.4pp | -24.7%-2.8pp | -21.9%+3.4pp | |
| Return on invested capital | -44.3%— | —— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 24×+2.1× | 21.9×-1.5× | 23.5×-8.7× | 32.1×-5.5× | 37.7×+16.5× | |
| Quick ratio | 24×+2.1× | 21.9×-1.5× | 23.5×-8.7× | 32.1×-5.5× | 37.7×+16.5× | |
| Cash ratio | 2.9×+0.4× | 2.5×-2.8× | 5.3×-0.9× | 6.2×-0.4× | 6.5×-1.7× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -74.7×-9.3× | -65.4×-3.7× | -61.8×— | —— | —— | |
| Per Share | ||||||
| Book value per share | $17.89-14.7% | $20.96+28.6% | $16.30-7.0% | $17.54-11.5% | $19.82+23.3% | |
| Valuation | ||||||
| Market capitalization | $2.44B-18.6% | $3B+30.5% | $2.3B+20.6% | $1.9B+11.0% | $1.72B-9.0% | |
| Enterprise value | $2.38B-18.9% | $2.94B+34.3% | $2.19B+21.0% | $1.81B+11.4% | $1.62B-5.8% | |
| Price / book | 3.5×-0.5× | 4.1×0.0× | 4×+0.9× | 3.1×+0.5× | 2.6×-1.7× | |
| Free cash flow yield | -8.3%-2.2pp | -6%+1.2pp | -7.2%-0.1pp | -7.1%-1.1pp | -6%-1.0pp | |
| Earnings yield | -9.9%-2.8pp | -7.1%+0.8pp | -7.9%-0.3pp | -7.6%-0.8pp | -6.8%-1.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Disc Medicine's ratios come from?
- Every ratio is computed from Disc Medicine's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.